PARP inhibitor treatment and survival in ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how PARP inhibitor maintenance therapy affects survival in people with ovarian, fallopian tube, or peritoneal cancer. It compares outcomes for those newly diagnosed at an advanced stage and those with a first recurrence that responded to platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer between December 2013 and December 2024.
- For newly diagnosed: your cancer was stage IIIC or IV at diagnosis.
- For recurrence: you had a first recurrence that responded to platinum-based chemotherapy, and the cancer came back at least 6 months after finishing that treatment.
- Your cancer is not a rare subtype like clear cell or mucinous, and not borderline or non-epithelial.
- You have complete records of your first-line (or second-line for recurrence) treatment and follow-up.
- You have not had a second relapse (for the recurrence group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how eating habits may affect the outlook for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor. By understanding your diet, researchers hope to find ways to improve treatment results.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests whether a supervised exercise and nutrition program can improve well-being for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor after finishing their first round of chemotherapy. Participation may help manage side effects and support overall health.
Hear when a new PARP Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.